EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

B7-H3 Inhibitors in Oncology Clinical Trials: A Review

Kavanya Feustel iD, Jared Martin, Gerald S Falchook

Journal of Immunotherapy and Precision Oncology · 01.02.2024 · 7 (1) · 53-66

DOI: 10.36401/jipo-23-18 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 05.02.2024. Verfasst von Kavanya Feustel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Early Phase Clinical Trials Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents showing promising preliminary clinical efficacy, observed with several of these agents against multiple tumor types. Particularly promising treatments are enoblituzumab for prostate cancer, 131I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. There are clinical trials on the horizon that have not yet enrolled patients examining chimeric antigen receptor T-cell therapies, bi- and tri-specific killer engagers, and dual-affinity retargeting proteins. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials.

Schlagwörter

Stichwörter der Autor:innen

B7-H3CD276cancerclinical trialreview

Autor:innen und Institutionen

  • Early Phase Clinical Trials Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
  • Rocky Vista University Medical School, Greenwood Village, CO, USA.

ORCID-Profile: Kavanya Feustel

Zitieren

APA

Feustel, K., Martin, J., & Falchook, G. S. (2024). B7-H3 Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology, 7(1), 53-66. https://doi.org/10.36401/jipo-23-18

Vancouver

Feustel K, Martin J, Falchook GS. B7-H3 Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology. 2024;7(1):53-66. doi:10.36401/jipo-23-18

BibTeX
@article{Feustel2024,
  author = {Feustel, Kavanya and Martin, Jared and Falchook, Gerald S},
  title = {B7-H3 Inhibitors in Oncology Clinical Trials: A Review},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2024},
  volume = {7},
  number = {1},
  pages = {53--66},
  doi = {10.36401/jipo-23-18}
}
Kostenlos starten →